全球丙肝病毒感染者已達(dá)到2億人，而以干擾素為基礎(chǔ)的標(biāo)準(zhǔn)治療存在諸多不足，開(kāi)發(fā)直接抗丙肝病毒藥物成為最新的研究方向。但是這類藥物單獨(dú)使用或與干擾素聯(lián)合使用時(shí)，病毒會(huì)產(chǎn)生耐藥性。因此為了滿足臨床需求，很多直接抗丙肝藥物的聯(lián)合治療方案正處于研究階段，對(duì)目前在研的直接抗丙肝藥物聯(lián)合治療方案的研究進(jìn)展做以簡(jiǎn)要綜述。

The number of people who infected hepatitis C virus (HCV) has been more than 200 million all over the world. However, there are several drawbacks in the standard treatments of HCV based on interferon, thus the development of the direct anti HCV agents will be the frontier. Due to the resistance from the single use or the combination of direct anti HCV agents with interferon, researchers are ongoing to develop the combination treatments of two or more direct anti HCV agents without interferon. The development of the direct anti HCV agents combination therapy is reviewed in this paper.